Your browser doesn't support javascript.
loading
A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas.
Skorupan, Nebojsa; Ahmad, Mehwish I; Steinberg, Seth M; Trepel, Jane B; Cridebring, Derek; Han, Haiyong; Von Hoff, Daniel D; Alewine, Christine.
Affiliation
  • Skorupan N; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Ahmad MI; Medical Oncology Service, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Steinberg SM; Office of Research Nursing, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Trepel JB; Biostatistics & Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Cridebring D; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Han H; Molecular Medicine Division, Translational Genomics Research Institute, an Affiliate of City of Hope, Phoenix, AZ 85004, USA.
  • Von Hoff DD; Molecular Medicine Division, Translational Genomics Research Institute, an Affiliate of City of Hope, Phoenix, AZ 85004, USA.
  • Alewine C; Molecular Medicine Division, Translational Genomics Research Institute, an Affiliate of City of Hope, Phoenix, AZ 85004, USA.
Future Oncol ; 18(20): 2475-2481, 2022 Jun.
Article in En | MEDLINE | ID: mdl-35535581
Adenosquamous carcinoma of the pancreas (ASCP) is a rare and highly aggressive variant of pancreatic cancer, with limited treatment options. Changes in activation of DNA elements called super-enhancers drive the growth of ASCP. Minnelide™ is an oral drug that blocks the super-enhancer network and is safe to give to patients with advanced cancer. This trial is designed to determine whether Minnelide can shrink tumors in patients with ASCP who have already received at least one previous treatment for their cancer.  Clinical Trial Registration: NCT04896073 (ClinicalTrials.gov).
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Adenosquamous / Carcinoma, Pancreatic Ductal Limits: Humans Language: En Journal: Future Oncol Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Adenosquamous / Carcinoma, Pancreatic Ductal Limits: Humans Language: En Journal: Future Oncol Year: 2022 Type: Article Affiliation country: United States